Patents by Inventor Biao He

Biao He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9359366
    Abstract: Disclosed are intermediates of Ticagrelor and a preparation method therefor, and a preparation method for Ticagrelor. Specifically, disclosed is an intermediate, namely, a compound of Formula (VI), for preparing Ticagrelor. Further disclosed is a method for preparing the intermediate and a method for preparing Ticagrelor by using the intermediate. Ticagrelor is prepared by using the intermediate, so that the synthesis process is simple, and a defect that long reaction times under high temperature that are required in the existing methods are avoided. The method is suitable for mass production in industry, energy consumption is reduced, pollution of the environment is reduced, and discharge of waste is reduced.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 7, 2016
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Suncadia Pharmaceuticals Co., Ltd.
    Inventors: Shaoguang Sun, Defu Song, Biao He, Xiaobo Lai
  • Patent number: 9279157
    Abstract: The present invention provides methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. The methods generally involve determining a normalized expression level of an EMX2 gene product, which correlates with prognosis and likelihood of survival.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: March 8, 2016
    Assignee: The Regents of the University of California
    Inventors: Biao He, David M. Jablons
  • Publication number: 20160052928
    Abstract: Disclosed are intermediates of Ticagrelor and a preparation method therefor, and a preparation method for Ticagrelor. Specifically, disclosed is an intermediate, namely, a compound of Formula (VI), for preparing Ticagrelor. Further disclosed is a method for preparing the intermediate and a method for preparing Ticagrelor by using the intermediate. Ticagrelor is prepared by using the intermediate, so that the synthesis process is simple, and a defect that long reaction times under high temperature that are required in the existing methods are avoided. The method is suitable for mass production in industry, energy consumption is reduced, pollution of the environment is reduced, and discharge of waste is reduced.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 25, 2016
    Inventors: Shaoguang SUN, Defu SONG, Biao HE, Xiaobo LAI
  • Publication number: 20150361048
    Abstract: The present disclosure provides compositions, pharmaceutical preparations and methods for the diagnosis and treatment of cancers expressing a GLI polypeptide. The disclosed compositions and pharmaceutical preparations may comprise one or more pyrazolyl-containing compounds, or an analog or derivative thereof.
    Type: Application
    Filed: January 22, 2014
    Publication date: December 17, 2015
    Inventors: Biao HE, Michael MANN, David M. JABLONS
  • Patent number: 9133524
    Abstract: The present disclosure provides methods and compositions for diagnosis and for providing a prognosis of a cancer patient by assessing CK2 alpha 1 pseudogene (CSNK2A1P) status. The present disclosure also provides polypeptide, polynucleotide, host cell, and transgenic animal compositions associated with CSNK2A1P.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: September 15, 2015
    Assignee: The Regents of the University of California
    Inventors: Liang You, Zhidong Xu, Biao He, David Jablons
  • Publication number: 20150239856
    Abstract: Disclosed in the present invention are 4-(5-amino-6-hydroxybenzoxazol-2-yl)ammonium benzoate shown in formula (I) and the preparation method and use thereof. The preparation method comprises: fully reacting 4-(5-amino-6-hydroxybenzoxazol-2-yl)benzoic acid shown in formula (II) or 4-(5-amino-6-hydroxybenzoxazol-2-yl)carboxamide benzoate, as a raw material, with ammonia in an aqueous solvent, and directly heating the obtained reaction liquid to remove excess ammonia, so as to obtain 4-(5-amino-6-hydroxybenzoxazol-2-yl)ammonium benzoate. The mass of the 4-(5-amino-6-hydroxybenzoxazol-2-yl)ammonium benzoate (ABAA) prepared in the present invention can reach a polymer grade (where the purity is above 99.
    Type: Application
    Filed: February 9, 2013
    Publication date: August 27, 2015
    Applicants: Zhejiang University of technology, Yancheng Dragon Chemical Co., Ltd.
    Inventors: Ningren Jin, Biao He, Jing Jin
  • Publication number: 20150086588
    Abstract: The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (PIV5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide. In some embodiments, the heterologous nucleotide sequence is inserted closer to the leader than between the hemagglutinin-neuroaminidase (HN) gene and the large RNA polymerase protein (L) gene of the PIV5 genome. In some embodiments, the heterologous nucleotide sequence is inserted between the small hydrophobic protein (SH) gene and the hemagglutinin-neuroaminidase (HN) gene of the PIV 5 genome.
    Type: Application
    Filed: January 24, 2013
    Publication date: March 26, 2015
    Inventor: Biao He
  • Publication number: 20140370050
    Abstract: The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5VAC), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI?), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI?, rPIV5-CPI+, rPIV-Rev, rPIV5-RL, rPIV5-P-5157A, rPIV5-P-5308A, A1981D, rPIV5-F-5443P, rPIV5-MDA7, rPIV5ASH-CPI?, or rPIV5ASH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents.
    Type: Application
    Filed: January 24, 2013
    Publication date: December 18, 2014
    Inventor: Biao He
  • Publication number: 20140303160
    Abstract: The present disclosure provides compositions, pharmaceutical preparations and methods for the diagnosis and treatment of cancers expressing a GLI polypeptide. The disclosed compositions and pharmaceutical preparations may comprise one or more pyrazolyl-containing compounds, or an analog or derivative thereof.
    Type: Application
    Filed: July 20, 2012
    Publication date: October 9, 2014
    Applicant: The Regents of the University of California
    Inventors: Biao He, Michael Mann, David M. Jablons
  • Patent number: 8823301
    Abstract: A device and method to determine the stopping rotor position of a washing machine motor includes an inverter, a permanent magnet synchronous motor, and an electronic motor controller. The controller determines the stopped rotor position of the motor by measuring induced currents in the stator field coils of the motor. While the motor is de-energized and slowly rotating, the controller directs the inverter to connect all of the stator field coils of the motor together. The stator field coils may be connected to a common D.C. rail, output from an A.C.-D.C. converter of the washing machine. In an embodiment, the controller determines the rotor position based on the polarities of current induced in the stator field coils. In another embodiment, the controller determines the rotor position based on the phase angle and angular frequency of the three phase currents, transformed into a stationary reference frame.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: September 2, 2014
    Assignee: Whirlpool Corporation
    Inventors: Biao He, Qiang Mei
  • Patent number: 8823298
    Abstract: A method of operating a laundry treating appliance to control a rotational speed of a drum to move the laundry within the drum according to a predetermined category of movement.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: September 2, 2014
    Assignee: Whirlpool Corporation
    Inventors: Biao He, Qiang Mei, Fabio E. Rosa
  • Publication number: 20140125265
    Abstract: A device and method to determine the stopping rotor position of a washing machine motor includes an inverter, a permanent magnet synchronous motor, and an electronic motor controller. The controller determines the stopped rotor position of the motor by measuring induced currents in the stator field coils of the motor. While the motor is de-energized and slowly rotating, the controller directs the inverter to connect all of the stator field coils of the motor together. The stator field coils may be connected to a common D.C. rail, output from an A.C.-D.C. converter of the washing machine. In an embodiment, the controller determines the rotor position based on the polarities of current induced in the stator field coils. In another embodiment, the controller determines the rotor position based on the phase angle and angular frequency of the three phase currents, transformed into a stationary reference frame.
    Type: Application
    Filed: November 5, 2012
    Publication date: May 8, 2014
    Applicant: WHIRLPOOL CORPORATION
    Inventors: BIAO HE, QIANG MEI
  • Publication number: 20140010840
    Abstract: The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuVIowa/us/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to MuVIowa/us/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuV?SH) and/or incapable of expressing the V protein (rMuV?V).
    Type: Application
    Filed: February 24, 2012
    Publication date: January 9, 2014
    Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventor: Biao He
  • Publication number: 20130273534
    Abstract: This invention provides compositions and methods for the diagnosis and treatment of cancers that exhibit decreased SOCS-3 expression.
    Type: Application
    Filed: March 7, 2013
    Publication date: October 17, 2013
    Inventors: Biao HE, Liang YOU, Zhidong XU, David M. JABLONS
  • Publication number: 20130241449
    Abstract: A method of operating a laundry treating appliance to control a rotational speed of a drum to move the laundry within the drum according to a predetermined category of movement.
    Type: Application
    Filed: March 14, 2012
    Publication date: September 19, 2013
    Applicant: WHIRLPOOL CORPORATION
    Inventors: BIAO HE, QIANG MEI, FABIO E. ROSA
  • Publication number: 20130230852
    Abstract: The present disclosure provides methods and compositions for diagnosis and for providing a prognosis of a cancer patient by assessing CK2 alpha 1 pseudogene (CSNK2A1P) status. The present disclosure also provides polypeptide, polynucleotide, host cell, and transgenic animal compositions associated with CSNK2A1P.
    Type: Application
    Filed: July 1, 2011
    Publication date: September 5, 2013
    Applicant: The Regents of the University of California
    Inventors: Liang You, Zhidong Xu, Biao He, David Jablons
  • Patent number: 8450062
    Abstract: This invention provides compositions and methods for the diagnosis and treatment of cancers that exhibit decreased SOCS-3 expression.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: May 28, 2013
    Assignee: The Regents of the University of California
    Inventors: Biao He, Liang You, Zhidong Xu, David M. Jablons
  • Publication number: 20110319337
    Abstract: The present disclosure provides compositions, pharmaceutical preparations, kits and methods for inhibiting cell proliferation by contacting a cell expressing Fzd8 with a truncated Wnt2 polypeptide which acts as a dominant negative inhibitor of Fzd8 signaling. The present disclosure provides compositions, kits and methods for the detection of cancer by determining the level of Fzd8 and/or Wnt2 expression in a cell.
    Type: Application
    Filed: December 30, 2009
    Publication date: December 29, 2011
    Inventors: Dawn Bravo, Liang You, Zhidong Xu, Biao He, David M. Jablons
  • Patent number: 7959923
    Abstract: This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such as a Frizzled receptor.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: June 14, 2011
    Assignee: The Regents of the University of California
    Inventors: Liang You, Biao He, Zhidong Xu, David M. Jablons
  • Publication number: 20100292162
    Abstract: This invention provides compositions and methods for the diagnosis and treatment of cancers that exhibit decreased SOCS-3 expression.
    Type: Application
    Filed: February 5, 2010
    Publication date: November 18, 2010
    Applicant: Regents of the University of California
    Inventors: Biao HE, Liang YOU, Zhidong XU, David M. JABLONS